J
Junwei Shi
Researcher at University of Pennsylvania
Publications - 78
Citations - 10689
Junwei Shi is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Transcription factor & Gene. The author has an hindex of 28, co-authored 62 publications receiving 8289 citations. Previous affiliations of Junwei Shi include Sun Yat-sen University & Stony Brook University.
Papers
More filters
Journal ArticleDOI
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore,Ghayas C Issa,Madeleine E. Lemieux,Peter B. Rahl,Junwei Shi,Hannah M. Jacobs,Efstathios Kastritis,Timothy Gilpatrick,Ronald M. Paranal,Jun Qi,Marta Chesi,Anna C. Schinzel,Michael R. McKeown,Timothy P. Heffernan,Christopher R. Vakoc,P. Leif Bergsagel,Irene M. Ghobrial,Paul G. Richardson,Richard A. Young,William C. Hahn,William C. Hahn,Kenneth C. Anderson,Andrew L. Kung,James E. Bradner,Constantine S. Mitsiades +24 more
TL;DR: In this paper, a small-molecule bromodomain inhibitor, JQ1, was used to identify BET proteins as regulatory factors for c-Myc oncoprotein.
Journal ArticleDOI
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber,Junwei Shi,Junwei Shi,Eric Wang,Amy R. Rappaport,Amy R. Rappaport,Harald Herrmann,Edward Allan R. Sison,Daniel Magoon,Jun Qi,Katharina Blatt,Mark Wunderlich,Meredith J. Taylor,Christopher Johns,Agustin Chicas,James C. Mulloy,Scott C. Kogan,Patrick Brown,Peter Valent,James E. Bradner,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe,Christopher R. Vakoc +23 more
TL;DR: The results establish small-molecule inhibition of Brd4 as a promising therapeutic strategy in AML and, potentially, other cancers, and highlight the utility of RNA interference screening for revealing epigenetic vulnerabilities that can be exploited for direct pharmacological intervention.
Journal ArticleDOI
Promoter-bound METTL3 maintains myeloid leukaemia by m 6 A-dependent translation control
Isaia Barbieri,Konstantinos Tzelepis,Luca Pandolfini,Junwei Shi,Gonzalo Millán-Zambrano,Samuel Robson,Demetrios Aspris,Valentina Migliori,Andrew J. Bannister,Namshik Han,Etienne De Braekeleer,Hannes Ponstingl,Alan G. Hendrick,Christopher R. Vakoc,George S. Vassiliou,Tony Kouzarides +15 more
TL;DR: Together, these data define METTL3 as a regulator of a chromatin-based pathway that is necessary for maintenance of the leukaemic state and identify this enzyme as a potential therapeutic target for acute myeloid leukaemia.
Journal ArticleDOI
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi,Christopher R. Vakoc +1 more
TL;DR: The current understanding of molecular mechanisms that underlie the promising therapeutic effects of BET bromodomain inhibition are reviewed.
Journal ArticleDOI
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
TL;DR: It is shown that the magnitude of negative selection can be used to infer the functional importance of individual protein domains of interest, and a broader application of this approach may allow comprehensive identification of protein domains that sustain cancer cells and are suitable for drug targeting.